[20] performed a retrospective cohort study with age‐ and PSA‐matched cis men and 199 trans women with prostate cancer, where the results showed that in 5 years of follow‐up after diagnosis, disease outcomes and mortality were comparable between both groups. This evidence concerns the gene KLK3 and prostate cancer.